Susan Desmond-Hellmann
Susan Desmond-Hellmann, MD, MPH, is chancellor of the University of California, San Francisco (UCSF). At UCSF, Desmond-Hellmann, an oncologist and renowned biotechnology leader, also holds appointment as Arthur and Toni Rembe Rock Distinguished Professor.
The recipient of numerous honors and awards, Desmond-Hellmann was inducted into the American Academy of Arts and Sciences and was elected to the Institute of Medicine in October 2010.
Before joining UCSF, she served as president of product development at Genentech, a position she held from March 2004 through April 30, 2009. In this role, she was responsible for Genentech?s pre-clinical and clinical development, process research and development, business development and product portfolio management. She also served as a member of Genentech?s executive committee, beginning in 1996. She joined Genentech in 1995 as a clinical scientist, and she was named chief medical officer in 1996. In 1999, she was named executive vice president of development and product operations. During her time at Genentech, several of the company?s patient therapeutics (Lucentis, Avastin, Herceptin, Tarceva, Rituxan and Xolair) were approved by the U.S. Food and Drug Administration, and the company became the nation?s No. 1 producer of anti-cancer drug treatments.In November 2009, Forbes magazine named Desmond-Hellmann as one of the world's seven most "powerful innovators," calling her "a hero to legions of cancer patients."
She completed her clinical training at UCSF and is board-certified in internal medicine and medical oncology. She holds a Bachelor of Science degree in pre-medicine and a medical degree from the University of Nevada, Reno, and a master?s degree in public health from the University of California, Berkeley.
Prior to joining Genentech, Desmond-Hellmann was associate director of clinical cancer research at Bristol-Myers Squibb Pharmaceutical Research Institute. While at Bristol-Myers Squibb, she was the project team leader for the cancer-fighting drug Taxol.Desmond-Hellmann also has served as associate adjunct professor of epidemiology and biostatistics at UCSF. During her tenure at UCSF, she spent two years as visiting faculty at the Uganda Cancer Institute, studying HIV/AIDS and cancer. She also spent two years in private practice as a medical oncologist before returning to clinical research.